--- title: "Merck & Company (MRK) news: class action" url: "https://aibio.space/companies/merck-mrk-nyse/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "MRK class action news: Merck faces securities class action over Gardasil demand in China, with derivative suits stayed. Merck & Company, Inc." --- MRK Merck & Company, Inc. NYSE · United States # Merck & Company (MRK) news MRK class action news Legal · 2026-08-07 ## [Merck faces securities class action over Gardasil demand in China, with derivative suits stayed](https://aibio.space/news/merck-faces-securities-class-action-gardasil-demand-china-derivative/) Cronin v. Merck in New Jersey names Merck and unnamed officers. The 10-Q gives no individual defendants; Merck's filings show its CEO, CFO and 13 director nominees. ## Latest Merck & Company news 1. 2026-01-08 Financings [Aktis Oncology prices upsized IPO at $18, raising about $318 million](https://aibio.space/news/aktis-oncology-prices-upsized-ipo-18-raising-about-318-million/) The radiopharmaceutical developer sold 17.65 million shares on the Nasdaq, the first U.S. biotech IPO of 2026, after raising its offering size. 2. 2025-07-29 Distress [Merck approves 2025 restructuring program with about $3.0 billion in pretax costs](https://aibio.space/news/merck-approves-2025-restructuring-program-about-3-0-billion-pretax/) Merck expects to eliminate certain positions in sales, administrative and research and development organizations and expects annual savings of approximately $1.7 billion, substantially realized by the end of 2027. ## Merck & Company at a glance - **Ticker**: MRK - **Listing**: NYSE - **Country**: United States - **Cash, Jun 30, 2026**: $7.14 billion ### Related companies - [Amylyx Pharmaceuticals](https://aibio.space/companies/amylyx-pharmaceuticals/) NASDAQ: AMLX - [Cumberland Pharmaceuticals](https://aibio.space/companies/cumberland-pharmaceuticals/) NASDAQ: CPIX - [Karyopharm Therapeutics](https://aibio.space/companies/karyopharm-therapeutics/) NASDAQ: KPTI - [NextCure](https://aibio.space/companies/nextcure/) NASDAQ: NXTC - [Oragenics](https://aibio.space/companies/oragenics/) AMEX: OGEN - [Tarsus Pharmaceuticals](https://aibio.space/companies/tarsus-pharmaceuticals/) NASDAQ: TARS - [Madrigal Pharmaceuticals](https://aibio.space/companies/madrigal-pharmaceuticals/) NASDAQ: MDGL - [Emergent BioSolutions](https://aibio.space/companies/emergent-biosolutions/) NYSE: EBS ### Also on NYSE - [Zoetis](https://aibio.space/companies/zoetis/) ZTS - [STERIS](https://aibio.space/companies/steris/) STE - [SMITH & NEPHEW](https://aibio.space/companies/smith-nephew/) SNN - [Cadre Holdings](https://aibio.space/companies/cadre/) CDRE - [USANA HEALTH SCIENCES INC](https://aibio.space/companies/usana-health-sciences/) USNA - [METTLER TOLEDO INTERNATIONAL INC/](https://aibio.space/companies/mettler-toledo-international/) MTD ## What Merck & Company does Merck & Co., Inc. is a global health care company that delivers innovative health solutions through prescription medicines, including biologic therapies, vaccines and animal health products. It runs two reportable segments, Pharmaceutical and Animal Health. The Pharmaceutical segment sells human health medicines and vaccines, mainly to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. Its lead product is Keytruda (pembrolizumab), an anti-PD-1 therapy approved for many cancer types, and Keytruda Qlex, a subcutaneous fixed combination of pembrolizumab and berahyaluronidase alfa. Welireg (belzutifan) treats certain von Hippel-Lindau disease-associated tumors and advanced renal cell carcinoma. Vaccines include Gardasil 9, which helps prevent certain cancers and diseases caused by human papillomavirus, along with ProQuad, M-M-R II and Varivax. Merck also records alliance revenue from Lynparza and Lenvima, and from Reblozyl. The Animal Health segment develops and markets veterinary pharmaceuticals and vaccines for livestock and companion animals, along with identification, traceability and monitoring products. | Product or program | What it is | Stage | |---|---|---| | Keytruda (pembrolizumab) | Anti-PD-1 therapy for many solid tumors and lymphomas | approved | | Keytruda Qlex | Subcutaneous fixed combination of pembrolizumab and berahyaluronidase alfa | approved in the U.S. | | Welireg (belzutifan) | Treats certain VHL disease-associated tumors and advanced renal cell carcinoma | approved | | Gardasil 9 | HPV vaccine to help prevent certain cancers and diseases | | Summarised from the company's [10-K filed Feb 24, 2026](https://www.sec.gov/Archives/edgar/data/310158/000031015826000063/mrk-20251231.htm). ## Merck & Company annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$65.01 billion](https://www.sec.gov/Archives/edgar/data/310158/000031015826000063/) | [$64.17 billion](https://www.sec.gov/Archives/edgar/data/310158/000031015826000063/) | | Research and development | [$15.79 billion](https://www.sec.gov/Archives/edgar/data/310158/000031015826000063/) | [$17.94 billion](https://www.sec.gov/Archives/edgar/data/310158/000031015826000063/) | | Net income (loss) | [$18.25 billion](https://www.sec.gov/Archives/edgar/data/310158/000031015826000063/) | [$17.12 billion](https://www.sec.gov/Archives/edgar/data/310158/000031015826000063/) | | Cash from operations | [$16.47 billion](https://www.sec.gov/Archives/edgar/data/310158/000031015826000063/) | [$21.47 billion](https://www.sec.gov/Archives/edgar/data/310158/000031015826000063/) | | Cash and equivalents | [$14.56 billion](https://www.sec.gov/Archives/edgar/data/310158/000031015826000212/) | [$13.24 billion](https://www.sec.gov/Archives/edgar/data/310158/000031015826000063/) | | Short-term investments | [$0](https://www.sec.gov/Archives/edgar/data/310158/000031015826000212/) | [$447.0 million](https://www.sec.gov/Archives/edgar/data/310158/000031015826000063/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $6.85 billion, plus short-term investments of $292.0 million, $7.14 billion in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Merck & Company Is there a class action against Merck & Company? Our latest story on this, dated Aug 7, 2026: "Merck faces securities class action over Gardasil demand in China, with derivative suits stayed". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/merck-faces-securities-class-action-gardasil-demand-china-derivative/). What is the ticker symbol of Merck & Company? Merck & Company, Inc. trades under the ticker MRK on NYSE. Where is Merck & Company listed? Merck & Company, Inc. is listed on NYSE. Our directory also records these other listings: BCBA:MRK; BCBA:MRK.CI; BCBA:MRKC; BCBA:MRKD; BIVA:MRK; BMFBOVESPA:MRCK34; BMV:MRK; BSESOF:6MK; BX:6MK; DUS:6MK; EUROTLX:4MRKX; FWB:6MK; GETTEX:6MK; HAM:6MK; HAN:6MK; LS:A0YD8Q; LSE:0QAH; LSX:A0YD8Q; MUN:6MK; NEO:MRK; SET:MRK03; SIX:MRK.USD; SWB:6MK; TRADEGATE:6MK; TSX:MRK; VIE:MRK; XETR:6MK. What is the SEC CIK of Merck & Company? The SEC Central Index Key (CIK) for Merck & Company, Inc. is 310158. Its filings are on SEC EDGAR. How many shares does Merck & Company have outstanding? 2,467,171,638 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-07. Which country or territory is Merck & Company listed under? Our directory records Merck & Company, Inc. under United States. What does Merck & Company do? Our directory classifies Merck & Company, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Merck & Company? The ISIN recorded for Merck & Company, Inc. is US58933Y1055. Does aibio.space cover Merck & Company? aibio.space lists Merck & Company, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Merck & Company incorporated? SEC records list its state or country of incorporation as NJ. What does Merck & Company develop? Merck & Co., Inc. is a global health care company that delivers innovative health solutions through prescription medicines, including biologic therapies, vaccines and animal health products. It runs two reportable segments, Pharmaceutical and Animal Health. What is Keytruda (pembrolizumab) from Merck & Company? Keytruda (pembrolizumab): Anti-PD-1 therapy for many solid tumors and lymphomas Stage: approved. What is Keytruda Qlex from Merck & Company? Keytruda Qlex: Subcutaneous fixed combination of pembrolizumab and berahyaluronidase alfa Stage: approved in the U.S.. What was Merck & Company's revenue last year? $65.01 billion for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is Merck & Company profitable? Merck & Company, Inc. reported net income of $18.25 billion for the fiscal year ended Dec 31, 2025, and generated $16.47 billion of cash from operations, per its annual report to the SEC. ## Investor discussion: Merck & Company Members talk about Merck & Company (MRK). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Merck & Company, newest first. Each line links the filing it comes from. 1. 2026-05-18 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/310158/000162828026035810/merck-preliminaryprospectu.htm) 2. 2026-05-04 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/310158/000162828026029802/mrk-20260331.htm) 3. 2026-04-07 Mergers A tender offer for its shares was filed. SEC Form SC TO-T. [Source](https://www.sec.gov/Archives/edgar/data/310158/000119312526144514/d43298dsctot.htm) 4. 2025-12-05 Mergers A tender offer for its shares was filed. SEC Form SC TO-T. [Source](https://www.sec.gov/Archives/edgar/data/310158/000119312525309877/d78449dsctot.htm) 5. 2025-12-01 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/310158/000162828025054305/merck-preliminaryprospectu.htm) 6. 2025-09-02 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/310158/000031015825000027/merckco-424bprelim.htm) 7. 2025-07-29 Distress Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.02,2.05,9.01). [Source](https://www.sec.gov/Archives/edgar/data/310158/000110465925071380/tm2521736d1_ex99-1.htm) 8. 2025-02-25 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/310158/000162828025007732/mrk-20241231.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NYSE:MRK on TradingView](https://www.tradingview.com/symbols/NYSE-MRK/). ## SEC filings and registration - **SEC name**: Merck & Co., Inc. - **CIK**: 310158 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: MRK (NYSE) - **State or country of incorporation**: NJ - **Fiscal year ends**: December 31 - **Filer category**: Large accelerated filer - **Business address**: 126 EAST LINCOLN AVENUE, RAHWAY, NJ, 07065 - **Phone**: 908-740-4000 - **Shares outstanding**: 2,467,171,638 as of 2026-07-31 (10-Q filed 2026-08-07) - **Former names**: Merck & Co. Inc.; SCHERING PLOUGH CORP ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/310158/000031015826000237/mrk-20261009.htm) filed 2026-10-13 - [10-Q](https://www.sec.gov/Archives/edgar/data/310158/000031015826000212/mrk-20260630.htm) filed 2026-08-07 - [8-K](https://www.sec.gov/Archives/edgar/data/310158/000110465926090045/tm2621496d1_8k.htm) filed 2026-08-04 - [8-K](https://www.sec.gov/Archives/edgar/data/310158/000110465926067509/tm2615833d1_8k.htm) filed 2026-05-28 - [8-K](https://www.sec.gov/Archives/edgar/data/310158/000162828026037738/mrk-20260522.htm) filed 2026-05-22 - [424B5](https://www.sec.gov/Archives/edgar/data/310158/000162828026036914/merck-prospectussupplement.htm) filed 2026-05-20 - [424B5](https://www.sec.gov/Archives/edgar/data/310158/000162828026035810/merck-preliminaryprospectu.htm) filed 2026-05-18 - [10-Q](https://www.sec.gov/Archives/edgar/data/310158/000162828026029802/mrk-20260331.htm) filed 2026-05-04 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000310158), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Merck & Company, Inc. is a public biotech or pharmaceutical company listed on NYSE under the ticker MRK, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Merck & Company, Inc. - **Ticker**: MRK - **Listing**: NYSE - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US58933Y1055 - **Other listed symbols**: BCBA:MRK; BCBA:MRK.CI; BCBA:MRKC; BCBA:MRKD; BIVA:MRK; BMFBOVESPA:MRCK34; BMV:MRK; BSESOF:6MK; BX:6MK; DUS:6MK; EUROTLX:4MRKX; FWB:6MK; GETTEX:6MK; HAM:6MK; HAN:6MK; LS:A0YD8Q; LSE:0QAH; LSX:A0YD8Q; MUN:6MK; NEO:MRK; SET:MRK03; SIX:MRK.USD; SWB:6MK; TRADEGATE:6MK; TSX:MRK; VIE:MRK; XETR:6MK - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NYSE-MRK/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/merck-mrk-nyse/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Merck & Company (MRK) news: class action", 2026-10-31, https://aibio.space/companies/merck-mrk-nyse/